RT Journal Article
SR Electronic
T1 Serological Analysis of New York City COVID19 Convalescent Plasma Donors
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.06.08.20124792
DO 10.1101/2020.06.08.20124792
A1 Luchsinger, Larry L.
A1 Ransegnola, Brett
A1 Jin, Daniel
A1 Muecksch, Frauke
A1 Weisblum, Yiska
A1 Bao, Weili
A1 George, Parakkal Jovvian
A1 Rodriguez, Marilis
A1 Tricoche, Nancy
A1 Schmidt, Fabian
A1 Gao, Chengjie
A1 Jawahar, Shabnam
A1 Pal, Mouli
A1 Schnall, Emily
A1 Zhang, Huan
A1 Strauss, Donna
A1 Yazdanbakhsh, Karina
A1 Hillyer, Christopher D.
A1 Bieniasz, Paul D.
A1 Hatziioannou, Theodora
YR 2020
UL http://medrxiv.org/content/early/2020/06/09/2020.06.08.20124792.abstract
AB Background The development of neutralizing antibodies (NAbs) against SARS-CoV-2, following infection or vaccination, is likely to be critical for the development of sufficient population immunity to drive cessation of the COVID19 pandemic. A large number of serologic tests, platforms and methodologies are being employed to determine seroprevalence in populations to select convalescent plasmas for therapeutic trials, and to guide policies about reopening. However, these tests have substantially variable sensitivity and specificity, and their ability to quantitatively predict levels of NAbs is unknown.Methods We determined levels of antibodies in convalescent plasma using commercially available SARS-CoV- 2 detection tests and in-house ELISA assays and correlated those measurements with neutralization activity measured using pseudotyped virus particles, which offer the most informative assessment of antiviral activity of patient sera against viral infection.Findings Our data show that a large proportion of convalescent plasma samples have modest antibody levels and that commercially available tests have varying degrees of accuracy in predicting neutralizing activity. Nevertheless, we found particular commercially available tests are capable of accurately measuring levels of antibodies that strongly correlate with neutralization assays.Interpretation Our findings imply that SARS-CoV-2 convalescent plasma donors have a wide range of antibody concentrations. At present it is unclear how antibody acquisition, particularly for low titer individuals, might afford future immunity to SARS-CoV-2. Further research will be required to determine the minimum threshold of antibody and neutralization activity necessary to accurately predict immunity. Correlation of clinical antibody tests with neutralization activity in this study could serve as a valuable ‘roadmap’ to guide the choice and interpretation of serological tests for SARS-CoV-2.Funding NIH NIAID, R01AI78788 (to TH) and R37AI64003 (to PDB)Competing Interest StatementThe authors have declared no competing interest.Funding StatementFunding source for TH, PBD, FM, YW and FS were NIH R01AI78788 and R37AI064003. Funding sources did not have a role in the writing of the manuscript or the decision to submit for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The New York Blood Center IRB has determined this project does not meet the definition of human subject research under the purview of the IRB according to federal regulations. IRB Reference ID: 1596981-1 IRB Reference Title: COVID19 Convalescent Plasma Serology TestingAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesRaw data will be made available upon request.